MedTrace Logo

Efficacy and Safety Study of RT001 to Treat Moderate to Severe Lateral Canthal Lines

NCT00968942 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2013-11-19

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety and efficacy of 2 sequential doses of RT001 compared to placebo gel to treat moderate to severe lateral canthal lines in adults.

Conditions

  • Lateral Canthal Lines
  • Crow's Feet
  • Facial Wrinkles

Interventions

DRUG

Botulinum Toxin Type A

RT001 (Botulinum Toxin Type A Topical Gel) Dose A applied topically at Baseline (Day 0) and at Week 4 on the lateral canthal areas

DRUG

Placebo

Placebo (Dose B) applied topically at Baseline (Day 0) and at Week 4 on the lateral canthal areas

Sponsors & Collaborators

  • Revance Therapeutics, Inc.

    lead INDUSTRY

Principal Investigators

  • Frederic S Brandt, M.D. · Dermatology Research Institute, LLC.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
30 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-08-31
Primary Completion
2009-10-31
Completion
2009-10-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00968942 on ClinicalTrials.gov